Eli Lilly disclosed phase 1 results for its amylin analog eloralintide, revealing an 11% body weight reduction coupled with a tolerable safety profile. Analysts view this as a strong indicator for the drug’s potential role in combination therapies like Zepbound, positioning it as a competitive player in obesity treatment markets. These data underscore continued momentum in peptide-based weight management agents.